SCHEMBL4053237

SCHEMBL4053237

Clc1ccc(CCc2nc3ncc(-c4ccco4)cc3[nH]2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 3/20 0.42
NOS1 P29475 3/20 0.42
NOS2 P35228 3/20 0.42
ADORA2A P29274 3/20 0.37
CACNA1B Q00975 1/20 0.36
APBA1 Q02410 1/20 0.36
CASP3 P42574 1/20 0.36
ALDH1A1 P00352 3/20 0.35
MAPT P10636 3/20 0.35
KDM4E B2RXH2 2/20 0.35
POLB P06746 2/20 0.35
TUBB4A P04350 1/20 0.35
TUBB P07437 1/20 0.35
TUBA3C P0DPH7 1/20 0.35
TUBA1B P68363 1/20 0.35
TUBA4A P68366 1/20 0.35
TUBB4B P68371 1/20 0.35
TUBB3 Q13509 1/20 0.35
TUBB2A Q13885 1/20 0.35
TUBB8 Q3ZCM7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4060932 0.90 MAPT (0.42) NOS3NOS1NOS2ADORA2ACASP3
SCHEMBL4060650 0.90 NOS3 (0.49) NOS3NOS1NOS2ADORA2AALDH1A1
SCHEMBL4056418 0.89 NOS1 (0.41) NOS3NOS1NOS2ADORA2AALDH1A1
SCHEMBL4058842 0.89 MEN1 (0.41) NOS3NOS1NOS2ADORA2AALDH1A1
SCHEMBL4058313 0.89 NOS1 (0.44) NOS3NOS1NOS2ADORA2AMAPT
SCHEMBL4054880 0.89 NOS3 (0.42) NOS3NOS1NOS2ADORA2AALDH1A1
SCHEMBL4055225 0.88 NOS1 (0.42) NOS3NOS1NOS2ADORA2AMAPT
SCHEMBL4055769 0.86 NOS1 (0.54) NOS3NOS1NOS2ADORA2AALDH1A1
SCHEMBL4053616 0.86 NOS3 (0.40) NOS3NOS1NOS2ADORA2AALDH1A1
SCHEMBL4056451 0.86 TRPV1 (0.44) NOS3NOS1NOS2ADORA2AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B NOS3 907/4885NOS1 879/4885NOS2 1019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.